Altimmune, Inc.ALTNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank86
3Y CAGR+45.0%
5Y CAGR-9.3%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
+45.0%/yr
vs -7.8%/yr prior
5Y CAGR
-9.3%/yr
Recent acceleration
Acceleration
+52.8pp
Accelerating
Percentile
P86
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
202534.02%
202415.60%
20235.85%
202211.17%
202116.68%
202055.39%
2019-12.95%
201815.47%
2017-26.55%
201685.06%